TYME - Tyme Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Tyme Technologies, Inc.

17 State Street
7th Floor
New York, NY 10004
United States

Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven E. HoffmanCo-Founder, Chairman, CEO & Chief Science Officer900.44kN/A1963
Mr. Ben R. TaylorPres & CFO623.29kN/A1977
Mr. James Biehl J.D.Chief Legal Officer & Sec.730.78kN/A1964
Ms. Michele Ilene KorfinChief Operating OfficerN/AN/A1972
Ms. Barbara C. GalainiPrincipal Accounting Officer & Corp. ControllerN/AN/A1958
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in Phase II clinical trials to treat cancer, including pancreatic, lung, breast, prostate, and sarcoma cancers. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.

Corporate Governance

Tyme Technologies, Inc.’s ISS Governance QualityScore as of December 4, 2019 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.